Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
Tony M. Keaveny(University of California, Berkeley), Cesar Libanati(Amgen (United States)), José Zanchetta(Universidad del Salvador), Michael R. McClung(Bone Health and Osteoporosis Foundation), Jacques P. Brown(Centre hospitalier de l'Université Laval), Harry K. Genant(University of California, San Francisco), Hoi-Shen Radcliffe(Amgen (United States)), Chris Recknor(Bone Health and Osteoporosis Foundation), Maria Luisa Brandi(Vita-Salute San Raffaele University), Richard Eastell(University of Sheffield), David L. Kopperdahl(O.N. Diagnostics (United States)), Stefan Goemaere(Ghent University Hospital), Klaus Engelke(Friedrich-Alexander-Universität Erlangen-Nürnberg), Thomas Fuerst(Synlab Czech (Czechia)), David L. Kendler(University of British Columbia)
Cited by 119
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k